Key takeaways
- Fibrinogen is the soluble protein that thrombin converts into the fibrin mesh of a clot, and it is also an acute-phase reactant produced by the liver in response to interleukin-6.
- A raised level therefore signals both a more clot-prone circulation and an inflammatory process running somewhere.
- Fibrinogen is a large soluble glycoprotein circulating at high concentration.
- Fibrinogen is synthesised in the liver, and its production is upregulated by interleukin-6 — the same cytokine that drives C-reactive protein (Bode et al., Eur J Cell Biol 2012).
- Most laboratories use a functional assay that measures how fast plasma clots after excess thrombin is added, and converts that time into a concentration.
Fibrinogen is unusual among blood markers in that it belongs to two systems at once. It is the raw material of every clot you form, and it is an inflammatory protein produced on demand by the liver. That dual identity is what makes it informative — a raised fibrinogen tells you both that the blood is more inclined to clot and that something is driving inflammation — and it is also what makes it easy to over-interpret. This is a marker worth measuring and worth being careful with.
What fibrinogen is and what it does
Fibrinogen is a large soluble glycoprotein circulating at high concentration. When clotting is triggered, thrombin cleaves it into fibrin monomers, which polymerise into the mesh that gives a clot its structure. Platelets provide the initial plug; fibrin is the scaffolding that turns it into something durable. It also binds platelets to each other, so it participates in aggregation as well as in the mesh itself.
Concentration matters mechanically, not just biochemically. More fibrinogen produces a denser fibrin network with thinner fibres, and that structure is more resistant to being broken down. It also raises plasma viscosity, which is part of why the marker relates to stroke as well as to coronary events.
The second job: acute-phase protein
Fibrinogen is synthesised in the liver, and its production is upregulated by interleukin-6 — the same cytokine that drives C-reactive protein (Bode et al., Eur J Cell Biol 2012). Any inflammatory stimulus therefore raises it: infection, injury, surgery, autoimmune activity, and the low-grade chronic inflammation of visceral adiposity.
This is why fibrinogen and hs-CRP correlate, and why they are not interchangeable. CRP is a purer inflammatory signal that responds quickly and falls quickly. Fibrinogen responds more slowly, sits at a much higher baseline concentration, and carries a functional consequence of its own. When both are raised, the inflammatory interpretation is stronger. When fibrinogen is raised and CRP is not, the more likely explanations are smoking, oral estrogen, age or genetics.
How it is measured, and why the number wobbles
Most laboratories use a functional assay that measures how fast plasma clots after excess thrombin is added, and converts that time into a concentration. It reports clottable fibrinogen — the fraction that actually works — which is what you want, but it means the result depends on assay and instrument. Comparing a value from one laboratory against a reference range from another is not reliable.
Biological variation is also substantial. A single measurement in an individual moves considerably between draws, and an unremarkable cold in the preceding week is enough to lift it. Never act on one fibrinogen result. If it is high, repeat it at least a few weeks later with no intercurrent illness, and interpret it alongside an inflammation marker drawn at the same time.
Ranges
- Optimal: 200-350 mg/dL
- Typical reference: 200-400 mg/dL
- Elevated: above 400 mg/dL
Low fibrinogen is a different and rarer problem — liver failure, consumption in disseminated intravascular coagulation, or an inherited deficiency — and is a haematological question rather than a risk-marker one.
What raises it, and why
- Chronic inflammation of any origin, through the IL-6 pathway described above
- Smoking, one of the strongest modifiable drivers; levels fall progressively after quitting (Sinha et al., Eur J Cardiovasc Prev Rehabil 2005)
- Visceral adiposity and metabolic syndrome — visceral fat is an active source of IL-6, which is why this marker tracks waist rather than weight
- Oral estrogen, including combined contraceptives and oral hormone therapy. This is a first-pass hepatic effect: swallowed estrogen reaches the liver at high concentration and alters production of coagulation proteins in a way that transdermal delivery largely avoids (Canonico et al., Circulation 2007). See estradiol and cardiovascular risk.
- Pregnancy, physiologically and substantially
- Acute infection or injury, transiently — the reason a single reading is unreliable
- Diabetes and insulin resistance
- Age, which raises baseline steadily and cannot be modified
What it predicts
Raised fibrinogen is associated with coronary events, stroke, venous thromboembolism and all-cause mortality, and the association survives adjustment for the conventional risk factors. The pooled individual-participant analysis established this at a scale that leaves little doubt about the association itself (Danesh et al., JAMA 2005).
"Independent predictor" is a statistical statement and is often heard as more than it is. It means fibrinogen carries information that the other measured variables did not. It does not mean fibrinogen is doing the damage.
Marker or cause?
This is the part usually left out, and it changes what you should do about a high result.
Because fibrinogen levels are partly genetically determined, it is possible to test causality directly: if people who inherit variants that raise lifetime fibrinogen also have more heart disease, the relationship is likely causal. If they do not, fibrinogen is more likely a marker travelling alongside the real drivers. Mendelian randomisation studies have not supported a causal role for fibrinogen in coronary disease (Keavney et al., Int J Epidemiol 2006), a conclusion reinforced by later genome-wide work (Sabater-Lleal et al., Circulation 2013).
The practical consequence: fibrinogen is a readout, not a target. There is no reason to try to lower the number for its own sake, and no drug is given for that purpose. Its value is that it points at the inflammatory and metabolic processes generating it — and those are worth treating. This is the same logic that applies to most inflammatory markers, and the opposite of the logic that applies to ApoB, which the same style of genetic evidence does support as causal.
Where it fits
Fibrinogen is a supporting marker, not a headline one. In a full cardiovascular assessment the order of importance is roughly: ApoB for the atherogenic particle burden, Lp(a) once in a lifetime for inherited risk, blood pressure, glucose and insulin for metabolic status, then inflammation — hs-CRP first, fibrinogen alongside it (inflammation markers explained sets out the full panel).
Where it earns its place is in resolving ambiguity. Someone with unremarkable lipids and a raised fibrinogen and CRP has a different risk profile from someone with the same lipids and neither, and that difference should change how aggressively the modifiable factors get pursued.
What moves it, and how fast
Everything that lowers fibrinogen does so by removing an inflammatory or metabolic driver rather than acting on fibrinogen itself. Smoking cessation is the largest single lever, with levels falling progressively over months to years rather than immediately. Regular aerobic exercise lowers it modestly (Ernst, Br J Sports Med 1993). Loss of visceral fat, better glycaemic control, treating sleep apnoea, a Mediterranean-pattern diet, and switching oral estrogen to transdermal where clinically appropriate all move it in the right direction.
Expect months, not weeks. A sensible retest is three to six months after a genuine change in one of those inputs — and the point of the retest is to confirm that the underlying process improved, not to chase a number into a range.
The clinical pearl: treat fibrinogen as a symptom of something rather than a problem in itself. A persistently raised value in a non-smoker with normal CRP deserves an explanation — visceral adiposity, insulin resistance, oral estrogen, an unrecognised inflammatory condition — and finding that explanation is worth far more than the number itself.
Bottom line
Fibrinogen is both the structural protein of a clot and an IL-6-driven acute-phase reactant, so a raised level signals a more clot-prone circulation and an inflammatory process at once. Optimal is 200-350 mg/dL; above 400 warrants a repeat and an explanation. It independently predicts cardiovascular events, stroke and venous thromboembolism, but genetic evidence does not support it as a cause — which makes it a useful pointer rather than a treatment target. Measure it alongside hs-CRP, never act on a single reading, and treat what is raising it rather than the number.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
